Apr 25 |
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
|
Apr 19 |
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
|
Apr 9 |
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
|
Mar 15 |
Ensysce Biosciences reports Q4 results
|
Mar 15 |
ENSC Striding Toward Opioid Replacement
|
Mar 15 |
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
|
Feb 27 |
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
|
Feb 21 |
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
|
Feb 16 |
ENSC: Investors Should Pay Attention
|
Feb 15 |
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
|